---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-221791"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2025-09-29T23:59:59+00:00"
generated_at: "2026-05-17T05:22:11.810443+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Enanta reports positive Phase 2b topline data for zelicapavir in high-risk RSV adults

## Summary
- Phase 2b study of zelicapavir (formerly EDP-938) met primary endpoint in high-risk adults with RSV.
- Topline results announced September 29, 2025; detailed data presented in slide presentation.
- Zelicapavir is an oral antiviral; no specific efficacy or safety numbers disclosed in the 8-K.
- Positive outcome supports advancement; further details expected in future medical meetings.

## SEC filing metadata
- accession: 0001193125-25-221791
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2025-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000119312525221791/0001193125-25-221791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000119312525221791/d65423d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-221791
- JSON: https://secwatch.observer/filing/0001193125-25-221791.json
- Plain text: https://secwatch.observer/filing/0001193125-25-221791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.